Since, α-ER is primarily responsible for the progression of breast cancer and since hydroxytamoxifen, a metabolite of hormonal drug tamoxifen, showcased an excellent binding affinity with the receptor, our ligand may be beneficial as it inhibits the estrogen from binding with estrogen receptors, thereby inhibiting cancer cell proliferation. Here, ESR1 is linked to breast cancer.